NBIX · NASDAQ · STOCK
Neurocrine Biosciences (NBIX) Stock Analysis
$142.40
52W $122.14 – $186.12
66/100
$14.32B
20.2
0.40
⚠
Buy rating, but near-term risk/reward is unfavorable
The long-term recommendation is based on the composite investment score. The near-term risk/reward is based on nearby support and resistance levels. These can differ when a strong company trades close to resistance with support further below.
Is NBIX Bullish or Bearish?
Bullish.
Innellis AI committee rates Neurocrine Biosciences (NBIX) Buy with a composite score of 66/100
, based on 6 analysts with 83% agreement.
Last updated October 10, 2026.
What Would Change This View
- Upgrade to Strong Buy
- Requires a committee score of 75.0 — +8.70 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Watch
- Requires the score to fall below 55.0 — -11.30 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. Risk Analyst sees a compelling case — low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock. Portfolio Manager remains cautious — sector concentration is already high (hhi 2796.97). This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- ROE of 21.1% shows genuine earnings power backing the valuation — Value
- Revenue growing 34.4% YoY -- genuine top-line momentum — Growth
- EPS growing 101.3% YoY — Growth
- 5 consecutive earnings beats -- consistent execution — Growth
- MACD histogram positive -- bullish momentum — Technical
- Weekly trend (sideways) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
- Price-to-book of 4.3x prices in significant intangible value — Value
- Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of October 10, 2026
Overall Committee Score
66/100
Agreement
83%
Analysts
6
Conviction
High
Sector Rank
Top 1%
of 192 Healthcare peers
Value Analyst
neutral
59
/ 100 · High confidence
Fair value -- neither a bargain nor obviously overpriced
+ ROE of 21.1% shows genuine earnings power backing the valuation
− Price-to-book of 4.3x prices in significant intangible value
Growth Analyst
bullish
71
/ 100 · High confidence
Strong, accelerating growth with consistent execution
+ Revenue growing 34.4% YoY -- genuine top-line momentum
− Growth rate is decelerating quarter over quarter -- the trend line matters more than the level
Technical Analyst
bullish
61
/ 100 · High confidence
Price action is constructive -- trend and momentum agree
+ MACD histogram positive -- bullish momentum
Risk Analyst
bullish
80
/ 100 · Low confidence
Risk profile is manageable -- leverage, volatility, and event exposure all look contained
+ Low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock
Macro Analyst
bullish
65
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst
bullish
62
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
Portfolio Manager
bearish
30
/ 100 · Moderate confidence
The existing book itself argues for caution here, independent of how good this specific stock looks
− Sector concentration is already high (HHI 2796.97)
Investment Thesis Evolution
Committee score strengthened from 62.5 to 66.3.
- Conviction changed from moderate to high.
- Committee agreement increased notably from 67% to 83%.
- Bearish pressure eased: 1 signal(s) disappeared.
- Analyst(s) changed stance: Risk Analyst.
Analyst-level changes:
- Risk Analyst: stance neutral->bullish; score 58->80 (+22).
Comparing 2026-10-09 to 2026-10-10 (1 day apart).
Technical Analysis
RSI (14)
45.5
Neutral
MACD Histogram
0.652
Bullish Momentum
Trend Direction
Sideways
Weekly: Sideways
Market Structure
Mixed
Support
$133.61
Resistance
$142.66
Bollinger %B
0.42
Inside Bands
Price vs Moving Averages
EMA 9
$142.75
Below
EMA 21
$145.03
Below
EMA 50
$150.71
Below
EMA 200
$149.44
Below
Fundamental Analysis
Valuation
81
Growth
75
Profitability
93
Financial Health
95
Cash Flow
70
Valuation
P/E Ratio
20.2×
P/B Ratio
3.90×
PEG Ratio
0.20
Dividend Yield
0.00%
52W High
$186.12
52W Low
$122.14
Quality & Growth
ROE
1471.2%
ROA
1033.4%
Gross Margin
9796.7%
Operating Margin
2338.2%
Revenue Growth YoY
—
Debt / Equity
0.11
AI Fundamental Assessment
P/E ratio of 20.2 (inexpensive relative to a 15-40x range); Price-to-book of 3.9x; PEG ratio of 0.2 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 14.7%; Return on assets of 10.3%; Net margin of 20.9%; Gross margin of 98.0%; Current ratio of 1.87 (healthy short-term liquidity); Debt-to-equity of 0.11; Free cash flow per share is positive (8.62); Most recent quarter beat estimates by 1.5%; 5 consecutive earnings beats; EPS growth decelerating (+0.0% -> -27.2% QoQ); Average YoY EPS growth of 31.1%; Analyst estimates rising over recent quarters
Get the Full NBIX Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →